|
第57卷 第2期 2024-3
Necrotizing fasciitis resulted from foreign body ingestion and intestinal perforation in an incisional hernia: Report of a case |
......................... |
|
第57卷 第2期 2024-3
Application of artificial intelligence in endodontic microsurgery |
......................... |
|
第57卷 第2期 2024-3
A rare case of cerebral metastasis of malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1 |
......................... |
|
第57卷 第2期 2024-3
Ethic in commenting and clinical surgery journal publication: Emerging issue in the era of social media—A story from “Beall” to “Jaime” and independent researcher |
......................... |
|
第57卷 第2期 2024-3
Ophidascaris robertsi, the new emerging human parasite and neurosurgery |
......................... |
|
第57卷 第2期 2024-3
Tetanus toxoid IgG, usefulness in clinical surgery, and diagnostic property limitation |
......................... |
|
第57卷 第2期 2024-3
Deaths among surgeons while on duty: An important issue in surgery and occupational medicine that should not be disregarded |
......................... |
|
第57卷 第2期 2024-3
ChatGPT and its use in clinical surgery: A comment on its pro and con |
......................... |
|
第57卷 第2期 2024-3
Isolated spinal neurocysticercosis and pseudotumor cerebri: Tropical problem to be noted |
......................... |
|
第57卷 第2期 2024-3
Management of massive hemothorax resulting from traumatic diaphragm rupture with kidney avulsion injury by combined anterior thoracoabdominal approaches |
......................... |
|
第57卷 第2期 2024-3
Laparoscopic partial splenectomy for sclerosing angiomatoid nodular transformation: A case report and literature review |
......................... |
|
第57卷 第2期 2024-3
Using three-dimensional versus two-dimensional laparoscopy in sleeve gastrectomy: A case matched comparison |
......................... |
|
第57卷 第2期 2024-3
Effectiveness of placing prophylactic mesh with the Sugarbaker technique via laparoscopic abdominoperineal resection for rectal cancer: 1-year results |
......................... |
|
第57卷 第2期 2024-3
Nylon cable ties–assisted delay primary closure of fasciotomy wound in patients of forearm compartment syndrome |
......................... |
|
第57卷 第2期 2024-3
Prefabricated venous fl ap, an advanced free venous fl ap for distant transfer: An experimental rat study |
......................... |
|
第57卷 第1期 2024-1
Isolated lower leg monoplegia due to traumatic intraparenchymal hemorrhage |
......................... |
|
第57卷 第1期 2024-1
Reflections on the association between cholecystectomy, cholelithiasis, and colorectal cancer |
......................... |
|
第57卷 第1期 2024-1
Molluscum contagiosum, false positive, and incidence: Concern in surgery |
......................... |
|
第57卷 第1期 2024-1
New form of COVID-19 vaccine: A new advanced technology for fighting the remained problem |
......................... |
|
第57卷 第1期 2024-1
COVID-19 vaccination, acute appendicitis, interrelationship, and jointed probability: A concern |
......................... |
|
|
篇名 |
First-line Therapy with Lapatinib (Tykerb®) in Metastatic Breast Cancer that Progressed on Adjuvant Trastuzumab (Herceptin®) Treatment: Report of a Case |
作者 |
Ya-Fen Hsu, Fiona Tsui-Fen Cheng, Yen-Kung Chen, Chin-Chu Wu |
卷期/出版年月 |
43卷1期 (2010/2) |
頁次 |
47-52 |
摘要 |
Lapatinib is a novel treatment option for female breast cancer patients who have
HER2-positive advanced or metastatic breast cancer that has progressed after
previous treatment with other chemotherapeutic agents. We report herein a 50-yearold
perimenopausal female who had Stage IIB, T3N0M0, ER(-), PR(-), Her2(3+)
breast infiltrating ductal carcinoma and had only received adjuvant trastuzumab
therapy every three week of 2,640 mg given in total following skin sparing
mastectomy with immediate tissue expander reconstruction on March 2nd, 2007.
Her overall responses to trastuzumab were good until liver metastases were
discovered in June, 2008. Due to hepatic failure, instead of chemotherapy we tried
lapatinib at a dose lower than recommended. The patient received 750 mg/m2/day of
lapatinib for the first week, along with capecitabine (1,250 mg/m2) twice a day. Her
liver function showed improvement after one week of therapy, therefore we
increased the dose of lapatinib to 1,000 mg/m2/day. A month later, the number of
metastasis tumors remained stationary in numbers, but most of the
lymphadenopathy was less obvious and almost invisible. Four months later,
significant shrinkage of the pre-existing hepatic metastases was observed, and some
of the tumors were no longer detected which reflected complete remission from those
tumors. This present case corresponds with the previous evidence that lapatinib has
clinical activity in HER2-overexpressing breast cancer that is not responsive to
trastuzumab-containing therapy. Future studies regarding the impact of lapatinib on
earlier stages of breast cancer, as well as its application as first-line therapy, are
warranted. |
關鍵詞 |
HER2, lapatinib, metastatic breast cancer, trastuzumab |
分類 |
Case Report |
|